Kornimate/medical-research-clean huggingface dataset:
bariatric surgery for obesity

Conditions: Obesity and Obesity-related Medical Conditions; Bariatric Surgery Patients

Summary: obesity has reached pandemic proportions worldwide, and its increased prevalence is associated with a plethora of metabolic disturbances. the obese state is characterized by increased adipose tissue mass and disturbed function resulting in systemic lipid spillover and low-grade inflammation, which may contribute to the development of comorbidities such as type 2 diabetes mellitus (t2dm) and cardiovascular disease. the crosstalk between various metabolic organs such as the gut, liver, adipose tissue, and skeletal muscle plays an important regulatory role in energy and substrate metabolism, which impacts metabolic health. the studies on the gut microbiota in host energy and substrate metabolism, \& its relation to obesity are neumerous, includes interventions that modify the gut microbiota composition and functionality with antibiotics , prebiotics \& probiotics . obesity-associated with metabolic conditions such as ( non alcoholic fatty liver diseases )nafld. obesity-associated nafld includes a spectrum of histological abnormalities ranging from steatosis to the inflammatory form of nafld, known as nash. it is frequently seen in severe obesity, and its prevalence has been found to increase up to 90% in such patients in some countries. so, in this study we compare liver status regarding degree of steatosis among different patients, using serum biomarkers scores and imaging techniques in obese patients undergo bariatric surgery ( case group ), and obese patients taking other lines of treatment ( control group ); to detect if bariatric surgery has better outcome for steatosis and inflammatory markers than other lines of management for obesity. - research outcome measures: a. primary (main): * compare liver status regarding steatosis using serum biomarkers scores in obese patients undergo bariatric surgery and obese patients taking other lines of treatment. * correlate these changes with weight loss and glycemic control. * secondary (subsidiary): * evaluate associations between these scores and insulin resistance, lipid profiles and inflammatory markers.


Eligibility criteria:
inclusion criteria: * two groups: * intervention group: 25 adults (bmi ≥30) undergoing sleeve gastrectomy or roux-en-y gastric bypass. * control group: 25 adults (bmi ≥30) managed with lifestyle/ dietary interventions. exclusion criteria: * prior bariatric surgery, inflammatory bowel disease, antibiotic/probiotic use (past 3 months), or severe hepatic/renal dysfunction.
phase 1 study of topical ocular pan-90806 for neovascular amd

Conditions: Age-Related Macular Degeneration (AMD)

Summary: the objective of this study is to assess the safety and tolerability of topical ocular pan-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular age-related macular degeneration (amd).


Eligibility criteria:
inclusion criteria: * diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (cnv) lesions secondary to neovascular amd * aged 50 years or older * demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye exclusion criteria: * no prior ocular or systemic treatment or surgery for neovascular amd in the study eye * history of or current clinical evidence in the study eye of: * aphakia * diabetic macular edema * any ocular inflammation or infections * pathological myopia * retinal detachment * advanced glaucoma * significant media opacity, including cataract * history or evidence of the following surgeries in the study eye: * penetrating keratoplasty or vitrectomy; * corneal transplant; * corneal or intraocular surgery within 3 months of screening * uncontrolled hypertension despite use of antihypertensive medications * participation in any investigational drug or device study, systemic or ocular, within past 3 months * women who are pregnant or nursing * known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the pan-90806 formulation

Keywords: neovascular age-related macular degeneration amd macular degeneration age-related macular degeneration wet amd neovascular amd exudative amd
combination of micropulse laser with or without photodynamic therapy for chronic central serous chorioretinopathy

Conditions: Central Serous Chorioretinopathy; Micropulse Laser; Photodynamic Therapy

Summary: in this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. the visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. we will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.


Eligibility criteria:
inclusion criteria: * age \>18 years old. * the patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. the diagnostic criteria for chronic csc were as follows: ffa examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. fundus examination showed superficial detachment of retinal neuroepithelium in macula. * patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment. * patients had follow-up data before and after treatment for 1 month and at least 6 months. exclusion criteria: * patients with other fundus diseases or refractive interstitial opacity. * during treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received. * various reasons led to incomplete patient data.
study evaluating single and repeated intravitreal doses of icon-1 in patients with uveal melanoma

Conditions: Uveal Melanoma; Choroid Neoplasm

Summary: the purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of icon-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.


Eligibility criteria:
inclusion criteria: * males or females of any race at least 18 years of age * clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye * planned enucleation or brachytherapy of the study eye due to uveal melanoma exclusion criteria: * uveal melanoma in the study eye originating in the anterior uveal tract (iris) * hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia) * woman who is pregnant or lactating
a longitudinal study of hermansky-pudlak syndrome pulmonary fibrosis

Conditions: Hermansky Pudlak Syndrome

Summary: hermansky-pudlak syndrome (hps) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including hps-1, hps-2, and hps-4. pulmonary fibrosis causes shortness of breath and progressive decline in lung function. in hps patients with at-risk subtypes, almost all adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation. the purpose of this study is to identify the earliest measurable pulmonary disease activity in individuals at-risk for hps pulmonary fibrosis. the study also aims to develop biomarkers that will aid in understanding of the causes of hps pulmonary fibrosis and facilitate more rapid conduct of therapeutic trials in hps patients with mild pulmonary disease in the future.


Eligibility criteria:
inclusion criteria: * individuals ages 12-90 years with confirmed diagnosis of hps as defined by verification of reduced or absent platelet dense granules by electron microscopy and/or genetic diagnosis * ability to provide informed consent, or consent of parent/guardian and assent for minors exclusion criteria: * status-post lung transplantation * perceived unsuitability for participation in the study in the opinion of the investigator
core biopsy endo sonography study evaluation of the significance of the pro-core® needle

Conditions: Pancreatic Neoplasm

Summary: the study is designed to evaluate the diagnostic accuracy of a new designed endoscopic ultrasonography (eus) core biopsy aspiration needle in comparison to a conventional eus aspiration needle in gi-tumors.

endoscopic ultrasound is an established examination method for tumors of the gastrointestinal tract and the pancreas. since imaging by itself is limited in differential diagnosis of tumors, eus guided fine needle aspiration is seen as a valid complementary method. since fine-needle aspiration (fna) is mainly based on cytological diagnostics, this method is limited also because of lacking supplementary immune- histochemical diagnostics. here, the obtainment of little histologically evaluable tissue samples (punched barrels) would be of benefit. a new punch needle device called pro-core needle (cook)(22 / 19 gauges) offers the possibility of increasing numbers of valid extractions of histologically evaluable tissues due to a better targeted precision and maneuverability in comparison to other devices of that kind (tru-cut needles, e.g.). a little notch at the pinpoint allows the obtainment of little tissue samples, that will be kept within the device by aspiration. this study compares the obtainment of tissue by proc-core needle and conventional aspiration punction systems.

Eligibility criteria:
inclusion criteria: * clinical indication for endoscopic ultrasound diagnostics with fine needle biopsies * age greater than 18 years exclusion criteria: * difficult or impossible approach to desired structures due to anatomy (postoperative anatomy, e.g.) * cystic lesion, e.g. cystic pancreas tumors * coagulopathy * severe general condition of the patient * other contraindications for endoscopical ultrasound aided fine needle punction

Keywords: fine needle aspiration core biopsy endoscopic ultrasound space occupying process mediastinal, perigastral, perihilar suspect lymph nodes mediastinal, perigastral or perihilar diagnostic accuracy of eus guided core biopsy
efficacy of omegaboost to increase omega-3 levels in healthy individuals

Conditions: Dry Eye Syndromes; Age-Related Macular Degeneration; Omega 3 Index

Summary: the purpose of this study is to determine increases in the omega index test indicating optimal omega-3s particularly eicosapentaenoic acid (epa) and docosahexaenoic acid (dha) levels for overall systemic benefits including healthy cardiovascular health and cholesterol levels as shown in the omegaindex (omegaquant) research.


Eligibility criteria:
inclusion criteria: * not currently taking omega-3 supplements or fish oils * able to swallow softgel or chew gummies nutritional supplement daily for a 12 week period * able to make four (4) follow-up visits exclusion criteria: * allergy to fish or seafood * h/o atrial fibrillation, or at risk of afib * h/o congestive heart failure, heart disease, or prior myocardial infarction and/or cerebrovascular accident * noncompliance with study requirements

Keywords: omega-3s docosahexaenoic acid dha eicosapentaenoic acid epa omegaboost omega index test
assessment of change in atherosclerotic plaque by serial ccta

Conditions: Coronary Artery Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Coronary Arteriosclerosis

Summary: assessment of change in atherosclerotic plaque by serial ccta (across) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of ccta.


Eligibility criteria:
inclusion criteria: * patients who underwent clinically indicated ccta (index ccta) * mild to moderate stenosis (25-69%) on ccta * ≥1 clinical risk factors (smoking, htn, hdl\<40, premature fhx, m ≥45, f ≥55) for cad exclusion criteria: * acute coronary syndrome (unstable angina or mi) * positive (not equivocal) stress test * contraindications to statin

Keywords: coronary artery disease coronary computed tomography angiography statins coronary atherosclerosis
study of brain cools device in patients resuscitated from cardiac arrest

Conditions: Cardiac Arrest With Successful Resuscitation

Summary: this submission is a pilot in which the new iqool warming system device will be used to maintain the temperature of adult patients in cardiac arrest within a range of within a range of 32°c to 38.5°c (89.6°f to 101.3°f). the iqool warming system has received a 510 k clearance by the fda.

subjects will receive temperature management using the iqool. this is an fda approved device. managing temperature is part of standard care for this population and surface cooling is commonly employed. the following phases will be conducted as standard of care, and will be reviewed for this study: induction phase: when a subject is included in the study, the iqool will be connected to the patient and activated. the induction period will continue until the patient has reached the upper limit of the target temperature range (defined as 0.5°c above the target temperature). maintenance phase: set target temperature will be maintained for 24 hours. the maintenance phase begins when the subject temperature is within 0.5°c of goal temperature. the maintenance phase is completed 24 hours after first reaching below the upper limit of the target temperature range. rewarming phase: after 24 hours of maintenance, gradual rewarming at 0.25 °c/h will commence. when the subject reaches 37°c the ttm period is completed and the iqool will continue to provide fever control. post ttm fever control: the subject will be kept at a body temperature of 37°c until 72 hours after the cardiac arrest or earlier if the subject regains consciousness.

Eligibility criteria:
inclusion criteria: * in- or out-of-hospital cardiac arrest of all initial rhythms * adult patients (18 years of age and older) * unconscious on admission to hospital, defined as not following commands * indication for targeted temperature management exclusion criteria: * pregnancy * prisoner * active do not resuscitate order * any patient not expected to survive 72 hours * skin infection * skin wound affecting site of temperature exchange pads

Keywords: resuscitation cardiac arrest coma
cisplatin plus temozolomide compared with temozolomide in patients with mgmt promotor unmethylated glioblastoma

Conditions: Glioblastoma Multiforme of Brain

Summary: temozolomide provided significant and clinically meaningful benefit in mgmt gene promoter methylation glioblastoma. however, in unmethylated patients, the effect of temozolomide is limited. the aim of this study is to compare the effect of cisplatin plus temozolomide and temozolomide in patients with mgmt gene promoter unmethylation glioblastoma

60 patients with glioblastoma were recruited for this study based on the following eligibility criteria: age between 18 and 70, performance status of 0-1 (eastern cooperative oncology group performance status), histologically confirmed mgmt gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. all patients had adequate hematologic, hepatic, and renal function. patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded. 60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups

Eligibility criteria:
inclusion criteria: * age between 18 and 75, performance status of 0-1 (eastern cooperative oncology group performance status), histologically confirmed mgmt gene promoter unmethylation glioblastoma no cerebrospinal fluid and distant metastatic disease. adequate hematologic, hepatic, and renal function exclusion criteria: * younger than 18 years; with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities

Keywords: glioblastoma mgmt promoter unmethylation
investigation of the effect of lipikar baume ap+m

Conditions: Actinic Keratoses

Summary: application of lipikar baume ap+m at least twice daily for 4 weeks on one of the two arms according to a randomization scheme the purpose of this study is to observe the skin barrier function, transepidermal water loss and microbial changes in study participants with actinic field damage of both arms. it's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in germany, in adult subjects having ak (grade i to iii) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria. a total of 20 subjects will be enrolled. the study design consists in 4-week evaluation period, with 2 visits per subject: screening/baseline (day 0, day 28 (end of lipikar baume ap+m application)).


Eligibility criteria:
inclusion criteria: * male, female, diverse persons (\> 18yo) who are capable of giving consent * female patients are eligible if the subject is not a woman of childbearing potential (wocbp) or if she is postmenopausal (cessation of menstruation \>12 months) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) * signed informed consent * diagnosis of at least 4 actinic keratoses of the the forearm and/or back of the hand (each arm) * olsen grade i, ii and/or iii * subjects with similar severity and number of aks on each side symmetrically * the study participant is in good general condition for his or her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study exclusion criteria: * known or documented intolerance to any of the ingredients of lipikar baume ap+m * any planned ak treatment during the study * treatment of actinic keratoses in the application area within the past 3 months (e.g. photodynamic therapy, topical 5-fu, diclofenac, imiquimod, cryotherapy etc.) * suspected invasive squamous cell cancer in the application area * chronic wounds, erosions, pre-existing infected skin or inflammation which, in the opinion of the investigator, are in need of treatment other than the study product * suspected non-compliance * current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-fluorouracil * any systemic immunosuppressant given within the 8 weeks prior to the study (e.g. systemic prednisolone, azathioprine etc.) * locally applied retinoids, steroids, or other prescribed externals in the 4 weeks prior to the start of the study that, in the opinion of the study physician, necessitate exclusion * products containing glycolic or alpha-hydroxy acids applied locally in the application area in the last 4 weeks * participation in another clinical trial * participation in a clinical study within the last 30 days * family members or colleagues of the investigator * participant is in a position or has a relationship with the investigator that presents a potential conflict of interest
fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis

Conditions: Primary Axillary Hyperhidrosis

Summary: twenty patients with pah had 1 session of fractionated microneedle radiofrequency treatment. clinical improvement was evaluated using a hyperhidrosis disease severity scale (hdss) and photographs were taken using the starch-iodine test at every visit and 4 weeks, 8 weeks, and 24 weeks after the treatment. skin biopsies were obtained from 3 of the enrolled patients before and after treatment. the satisfaction and adverse reactions of the research participants were recorded at every follow-up visit.

hyperhidrosis disease severity scale (hdss)score = 1 my sweating is never noticeable and never interferes with my daily activitiesscore = 2 my sweating is tolerable but sometimes interferes with my daily activitiesscore = 3 my sweating is barely tolerable and frequently interferes with my daily activitiesscore = 4 my sweating is intolerable and always interferes with my daily activities

Eligibility criteria:
inclusion criteria: meet the following conditions * diagnosed according to having a score of 3 or 4 on a hyperhidrosis disease * severity scale (hdss); * patients aged 18 to 40 years (to the date of screening); * not treatment in axillary area before; * understanding the whole process of the study, voluntary participation and signed the informed consent; * patient compliance is good, can guarantee in course of observation. exclusion criteria:one of the following is not included in this study: * pregnant women, ready to pregnant or lactating women; * have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history * need insulin control of diabetes; high blood pressure did not get good controller ; * patients with white blood cells \<4.0 × 109 / l, or a definite anemia (hemoglobin less than 100g / l), or platelets \<100 × 109 / l, or other blood disease; * patients with chronic diarrhea, or peptic ulcer nearly 1 year; * patients suffering from malignant tumor; * patients suffering from acute and chronic infectious diseases; * mental disorders, history of alcohol abuse, drug or other substance abuse; * other cases which researchers believe that can not enroll.